The role of heparin binding surfaces in the direction of endothelial and smooth muscle cell fate and re-endothelialization

Biomaterials

Volumn 33, Issue 28, 2012, Pages 6615-6625

  Yang, Zhilu ^a   Tu, Qiufen ^a   Wang, Jin ^a   Huang, Nan ^a  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

Author keywords

Anticoagulation; Endothelial cells; Heparin; Smooth muscle cells; Vascular devices

Indexed keywords

ALLYL AMINE; ANTI-COAGULATION; ANTITHROMBOTIC; BIOLOGICAL FUNCTIONS; GROWTH BEHAVIOR; HEPARIN; HEPARIN BINDING; HUMAN BLOODS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; IN-VIVO; RELEASE OF NITRIC OXIDE; SMOOTH MUSCLE CELLS; THROMBOGENICITY; THROMBOSIS FORMATION; UMBILICAL ARTERY; VASCULAR CELLS; VASCULAR DEVICES;

CELL ADHESION; COATINGS; ENDOTHELIAL CELLS; GRAFTING (CHEMICAL); NITRIC OXIDE;

POLYSACCHARIDES;

HEPARIN; NITRIC OXIDE; PROSTACYCLIN; WARFARIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL ASSAY; CELL DEATH; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR PARAMETERS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REENDOTHELIZATION; SMOOTH MUSCLE FIBER; THROMBOGENICITY; THROMBOSIS; UMBILICAL ARTERY;

ALLYLAMINE; ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS; CELL ADHESION; CELL PROLIFERATION; DOGS; EPOPROSTENOL; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PROTEIN BINDING; SURFACE PROPERTIES; THROMBOSIS; UMBILICAL VEINS;

EID: 84864019062     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.055     Document Type: Article

References (54)

1. Ward M.R., Stewart D.J., Kutryk M.J. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives. Catheter Cardiovasc Interv 2007, 70:983-998.
2. Zilberman M., Eberhart R.C. Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng 2006, 8:153-180.
3. Eisenberg M.J., Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 2006, 98:375-382.
4. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108:788-794.
5. Avci-Adali M., Paul A., Ziemer G., Wendel H.P. New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials. Biomaterials 2008, 29:3936-3945.
6. 2 nanotube surfaces. Nano Lett 2008, 8:786-793.
7. Ku S.H., Park C.B. Human endothelial cell growth on mussel-inspired nanofiber scaffold for vascular tissue engineering. Biomaterials 2010, 31:9431-9437.
8. Poh C.K., Shi Z.L., Lim T.Y., Neoh K.G., Wang W. The effect of VEGF functionalization of titanium on endothelial cells in vitro. Biomaterials 2010, 31:1578-1585.
9. Zhu Y.B., Gao C.Y., Shen J.C. Surface modification of polycaprolactone with poly (methacrylic acid) and gelatin covalent immobilization for promoting its cytocompatibiltiy. Biomaterials 2002, 23:4889-4895.
10. Stephane B., Mireille A., Jacqueline M.B. Cell adhesive PET membranes by surface grafting of RGD peptidomimetics. Biomaterials 2005, 26:4576-4587.
11. Veleva A.N., Heath D.E., Cooper S.L., Patterson C. Selective endothelial cell attachment to peptide-modified terpolymers. Biomaterials 2008, 29:3656-3661.
12. Yin M., Yuan Y., Liu C.S., Wang J. Development of mussel adhesive polypeptide mimics coating for in-situ inducing re-endothelialization of intravascular stent devices. Biomaterials 2009, 30:2764-2773.
13. Li Q.L., Huang N., Chen C., Chen J.L., Xiong K.Q., Chen J.Y., et al. Oriented immobilization of anti-CD34 antibody on titanium surface for self-endothelialization induction. J Biomed Mater Res A 2010, 94A:1283-1293.
14. Beamish J.A., Geyer L.C., Haq-Siddiqi N.A., Kottke-Marchant K., Marchant R.E. The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype. Biomaterials 2009, 30:6286-6294.
15. Gu Z., Rolfe B.E., Xu Z.P., Thomas A.C., Campbell J.H., Lu G.Q.M. Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells. Biomaterials 2010, 31:5455-5462.
16. Clowes A.E., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
17. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed 2002, 41:391-412.
18. Thornton S.C., Mueller S.N., Levine E.M. Endothelial cells: use of heparin in cloning and long-term serial cultivation. Science 1983, 222:623-625.
19. Rubin H. Serine protease inhibitors (SERPINS): where mechanism meets medicine. Nat Med 1996, 2:632-633.
20. Azizkhan R.G., Azizkhan J.C., Zetter B.R., Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 1980, 152:931-944.
21. Castellot J.J., Choay J., Lormeau J.C., Petitou M., Sache E., Karnovsky M.J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol 1986, 102:1979-1984.
22. Garg H.G., Thompson B.T., Hales C.A. Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000, 279:L779-L789.
23. Casu B. Heparin structure. Haemostasis 1990, 20:62-73.
24. Kim Y.J., Kang I.K., Huh M.W., Yoon S.C. Surface characterization and in vitro blood compatibility of poly(ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge. Biomaterials 2000, 21:21-30.
25. Chen H., Chen Y., Sheardown H., Brook M.A. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials 2005, 26:7418-7424.
26. Huang X.J., Guduru D., Xu Z.K., Vienken J., Groth T. Blood compatibility and permeability of heparin-modified polysulfone as potential membrane for simultaneous hemodialysis and LDL removal. Macromol Biosci 2010, 10:131-140.
27. Li G.C., Yang P., Qin W., Maitz M.F., Zhou S., Huang N. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomaterials 2011, 32:4691-4703.
28. Yang Z.L., Zhou S., Lu L., Wang X., Wang J., Huang N. Construction and hemocompatibility study of highly bioactive heparin-functionalized surface. J Biomed Mater Res A 2012, 10.1002/jbm.a.34136.
29. Yang Z.L., Lei X.J., Wang J., Luo R.F., He T.T., Sun H., et al. A novel technique toward bipolar films containing alternating nano-layers of allylamine and acrylic acid plasma polymers for biomedical application. Plasma Process Polym 2011, 8:208-214.
30. Taylor M., Urquhart A.J., Zelzer M., Davies M.C., Alexander M.R. Picoliter water contact angle measurement on polymers. Langmuir 2007, 23:6875-6878.
31. Lawrie G., Keen I., Drew B., Chandler-Temple A., Rintoul L., Fredericks P., et al. Interactions between alginate and chitosan biopolymers characterized using FTIR and XPS. Biomacromolecules 2007, 8:2533-2541.
32. Yang Z.L., Tu Q.F., Wang J., Lei X.J., He T.T., Sun H., et al. Bioactive plasma-polymerized bipolar films for enhanced endothelial cell mobility. Macromol Biosci 2011, 11:797-805.
33. Tanaka M., Takayama A., Ito E., Sunami H., Yamamoto S., Shimomura M. Effect of pore size of self-organized honeycomb-patterned polymer films on spreading, focal adhesion, proliferation, and function of endothelial cells. J Nanosci Nanotechnol 2007, 7:763-772.
34. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24:4382-4415.
35. McCormick C., Wadsworth R.M., Jones R.L., Kennedy S. Prostacyclin analogues: the next drug-eluting stent?. Biochem Soc Trans 2007, 35:910-911.
36. Newby A.C., Southgate K.M., Assender J.W. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Herz 1992, 17:291-299.
37. Hardhammar P.A., van Beusekom H.M., Emanuelsson H.U., Hofma S.H., Albertsson P.A., Verdouw P.D., et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996, 93:423-430.
38. Vrolix M.C.M., Legrand V., Reiber J.H.C., Grollier G., Schalij M.J., Brunel P., et al. Heparin-coated wiktor stents in human coronary arteries (Mentor trial). Am J Cardiol 2000, 86:385-389.
39. ® - no influence on restenosis or clinical outcome. Eur Heart J 2001, 22:1808-1816.
40. Bartorelli A.L., De Cesare N.B., Kaplan A.V., Fabbiocchi F., Montorsi P., Squadroni L., et al. Local heparin delivery prior to coronary stent implantation: acute and six-month clinical and angiographic results. Cathet Cardiovasc Diagn 1997, 42:313-320.
41. Camenzind E., Kint P.P., Di Mario C., Jürgen L., Giessen W., Boersma E., et al. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation 1995, 92:2463-2472.
42. Gardais A., Picard J., Hermelin B. Glycosaminoglycan (GAG) distribution in aortic wall from five species. Comp Biochem Physil (B) 1973, 44:507-515.
43. Buonassisi V. Sulfated mucopolysaccharide synthesis and secretion in endothelial cell culture. Exp Cell Res 1973, 76:363-368.
44. Castellot J.J., Addonizio M.L., Rosenberg R., Karnovsky M.J. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981, 90:372-379.
45. Fernandez F., N'guyen P., Van Ryn J., Ofosu F.A., Hirsh J., Buchanan M.R. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986, 43:491-495.
46. Costachel O., Fadei L., Nachtigal M. The action of heparin in vitro on Syrian-hamster sarcoma-cell cultures. Exp Cell Res 1964, 34:542-547.
47. Gong F.R., Cheng X.Y., Wang S.F., Zhao Y.C., Gao Y., Cai H.B. Heparin-immobilized polymers as non-inflammatory and non-thrombogeniccoating materials for arsenic trioxide eluting stents. Acta Biomaterialia 2010, 6:534-546.
48. Stewart E.M., Liu X., Clark G.M., Kapsa R.M.I., Wallace G.G. Inhibition of smooth muscle cell adhesion and proliferation on heparin-doped polypyrrole. Acta Biomaterialia 2012, 8:194-200.
49. Kjellen L., Oldberg A., Rubin K., Hook M. Binding of heparin and heparan sulfate to rat liver cells. Biochem Biophys Res Commun 1977, 74:126-133.
50. Glimelius B., Busch C., Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978, 12:773-782.
51. Roblin R., Albert S.O., Gelb N.A., Black P.H. Cell surface changes correlated with density-dependent growth inhibition. Glycosaminoglycan metabolism in 3T3, SV3T3, and Con A selected revertant cells. Biochemistry 1975, 14:347-357.
52. Kraemer P.M., Smith D.A. High molecular-weigth heparan sulfate from the cell surface. Biochem Biophys Res Commun 1974, 56:423-430.
53. Abro A., Abraham K.A. Heparin effects on cultured mammalian cells. Experientia 1975, 31:1453-1456.
54. Yang Z.L., Wang J., Luo R.F., Maitz M.F., Jing F.J., Sun H., et al. The covalent immobilization of heparin to pulsed-plasma polymeric allylamine films on 316L stainless steel and the resulting effects on hemocompatibility. Biomaterials 2010, 31:2072-2083.